The U.S. IPO market staged a strong rebound in Q3 2025, with 34 deals raising $12.4 billion, according to Renaissance Capital’s quarterly review. Investor appetite returned for high-growth tech and healthcare names, while smaller offerings dominated in volume.
Company Background (Market Overview):
After a subdued first half of 2025, marked by rising interest rates and geopolitical concerns, Q3 saw stronger capital markets activity. Technology and biotech accounted for 45% of total deals, with consumer and industrial IPOs also making notable contributions.
IPO Details:
The average deal size in Q3 was $365 million, up 18% from Q2, while median pricing range compliance improved to 72%, signaling stronger demand. Notable offerings included CloudNova Technologies ($1.1B raise, up 38% post-listing) and Genex Bio ($900M raise, up 25%).
Market Context & Opportunities:
IPO performance benefited from easing inflation data and a stable 10-year Treasury yield at 3.9%. Institutional investors re-entered the market, with average first-day trading volumes up 22% compared to the previous quarter. The rebound suggests IPOs are regaining traction as a viable exit route for private equity and venture capital firms.
Risks & Challenges:
Despite the rebound, headwinds persist: regulatory tightening in tech, macro uncertainty in China, and ongoing volatility in energy markets. Investor selectivity remains high, with nearly 40% of IPOs pricing at the low end of their ranges.
Closing Paragraph:
Q3 2025 marked a turning point for the U.S. IPO market, but sustainability will depend on continued economic stability and investor risk appetite. With Q4 pipelines exceeding $20 billion, the coming months will determine if this momentum can carry into 2026.
